News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
14,703 Results
Type
Article (810)
Company Profile (18)
Press Release (13874)
Multimedia
Podcasts (2)
Webinars (2)
Section
Business (4789)
Career Advice (17)
Deals (678)
Drug Delivery (3)
Drug Development (2519)
Employer Resources (2)
FDA (236)
Job Trends (283)
News (7772)
Policy (425)
Tag
Academia (40)
Accelerated approval (2)
Adcomms (5)
Allergies (6)
Alliances (1344)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (20)
Approvals (235)
Artificial intelligence (8)
Autoimmune disease (6)
Automation (1)
Bankruptcy (4)
Best Places to Work (222)
BIOSECURE Act (5)
Biosimilars (11)
Biotechnology (14)
Bladder cancer (1)
Brain cancer (1)
Breast cancer (5)
Cancer (130)
Cardiovascular disease (12)
Career advice (10)
CAR-T (18)
CDC (1)
Cell therapy (60)
Clinical research (2036)
Collaboration (66)
Compensation (34)
Complete response letters (4)
COVID-19 (105)
CRISPR (7)
C-suite (43)
Cystic fibrosis (1)
Data (173)
Diabetes (13)
Diagnostics (43)
Drug discovery (9)
Drug pricing (1)
Earnings (1553)
Editorial (2)
Employer resources (2)
Events (2641)
Executive appointments (52)
FDA (315)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (53)
Gene editing (12)
Gene therapy (39)
GLP-1 (20)
Government (54)
Guidances (7)
Healthcare (401)
Immunology and inflammation (13)
Immuno-oncology (2)
Infectious disease (107)
Inflammatory bowel disease (10)
Intellectual property (6)
Interviews (3)
IPO (368)
Job creations (64)
Job search strategy (10)
JPM (3)
Kidney cancer (1)
Labor market (5)
Layoffs (21)
Legal (68)
Liver cancer (2)
Lung cancer (17)
Lymphoma (22)
Machine learning (1)
Management (1)
Manufacturing (31)
MASH (2)
Medical device (74)
Medtech (74)
Mergers & acquisitions (339)
Metabolic disorders (22)
Neurodegenerative disease (8)
Neuroscience (27)
NextGen: Class of 2026 (141)
Non-profit (28)
Now hiring (1)
Obesity (6)
Opinion (1)
Ovarian cancer (5)
Pain (9)
Pancreatic cancer (2)
Parkinson's disease (5)
Partnered (1)
Patents (11)
Patient recruitment (9)
People (1864)
Pharmacy benefit managers (1)
Phase 1 (924)
Phase 2 (984)
Phase 3 (583)
Pipeline (149)
Policy (14)
Postmarket research (25)
Preclinical (299)
Press Release (1)
Prostate cancer (3)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (38)
Real estate (122)
Recruiting (1)
Regulatory (430)
Reports (3)
Research institute (66)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (12)
Series B (5)
Service/supplier (1)
Sickle cell disease (2)
Special edition (2)
Spinal muscular atrophy (2)
Sponsored (2)
Startups (108)
Supply chain (2)
Tariffs (2)
The Weekly (2)
Vaccines (17)
Venture capital (4)
Weight loss (3)
Date
Today (3)
Last 7 days (16)
Last 30 days (54)
Last 365 days (853)
2026 (78)
2025 (877)
2024 (1074)
2023 (1311)
2022 (1716)
2021 (1734)
2020 (1300)
2019 (775)
2018 (580)
2017 (705)
2016 (589)
2015 (675)
2014 (460)
2013 (376)
2012 (327)
2011 (328)
2010 (348)
Location
Africa (17)
Arizona (1)
Asia (1320)
Australia (99)
California (509)
Canada (125)
China (52)
Colorado (5)
Connecticut (9)
Delaware (14)
Europe (1610)
Florida (33)
Idaho (1)
Illinois (7)
India (10)
Indiana (2)
Japan (16)
Maryland (67)
Massachusetts (234)
Michigan (4)
Minnesota (8)
Nevada (1)
New Jersey (75)
New Mexico (1)
New York (40)
North Carolina (22)
Northern California (225)
Oklahoma (1)
Pennsylvania (69)
South America (10)
Southern California (194)
Texas (38)
United States (1132)
Utah (2)
Virginia (1)
Washington D.C. (2)
Washington State (17)
Wisconsin (2)
14,703 Results for "biothera".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
December 12, 2025
·
7 min read
Press Releases
Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
August 24, 2025
·
6 min read
Press Releases
The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®
August 27, 2025
·
5 min read
Press Releases
Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in Canada
October 10, 2025
·
6 min read
Press Releases
Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi®
July 17, 2025
·
7 min read
Press Releases
Bio-Thera Solutions Receives Positive CHMP Opinion for USYMRO®(ustekinumab), a Biosimilar Referencing Stelara®
June 20, 2025
·
5 min read
Press Releases
Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America
June 25, 2025
·
5 min read
Business
Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM
Bio-Thera Solutions announced today a new licensing agreement for two biosimilars under which SteinCares will have exclusive rights to distribute and market Bio-Thera’s pharmaceuticals in Brazil and the rest of the region.
March 18, 2024
·
5 min read
Press Releases
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
May 27, 2025
·
14 min read
Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi® (bevacizumab), a Biosimilar Referencing Avastin®
Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Avzivi®, a biosimilar monoclonal antibody referencing AVASTIN®.
June 3, 2024
·
5 min read
1 of 1,471
Next
